Reported Saturday, ImmunityBio Secures Exclusive US Rights To Tokyo-172 BCG After Phase 3 Trial Shows Non-Inferior Efficacy To TICE BCG

Benzinga Newsdesk www.benzinga.com Positive 94.6%